SPONSOR
The Children's Hospital of Zhejiang University School of Medicine
Total Trials
6
Recruiting
6
Phases
EARLY_Phase 1, Phase 3
Conditions studied: Autoimmune DiseasesSystemic Lupus ErthematosusMulti-Drug Resistant Nephrotic SyndromeIgAN - IgA NephropathyNephrotic Syndrome in ChildrenRituximabAbdominal NeoplasmAbdominal InjuryAscitesANCA Associated Vasculitis
The Children's Hospital of Zhejiang University School of Medicine is a clinical research sponsor with 6 registered studies on ClinicalTrials.gov, of which 6 are actively recruiting participants. Research covers conditions including Autoimmune Diseases, Systemic Lupus Erthematosus, Multi-Drug Resistant Nephrotic Syndrome, IgAN - IgA Nephropathy.
The trial portfolio spans EARLY_Phase 1, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — The Children's Hospital of Zhejiang University School of Medicine
How many clinical trials has The Children's Hospital of Zhejiang University School of Medicine sponsored?
ClinicalMetric currently tracks 6 clinical trials sponsored by The Children's Hospital of Zhejiang University School of Medicine, of which 6 are actively recruiting participants. These trials cover conditions including Autoimmune Diseases, Systemic Lupus Erthematosus, Multi-Drug Resistant Nephrotic Syndrome. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does The Children's Hospital of Zhejiang University School of Medicine research focus on?
The Children's Hospital of Zhejiang University School of Medicine clinical trials span Autoimmune Diseases, Systemic Lupus Erthematosus, Multi-Drug Resistant Nephrotic Syndrome, IgAN - IgA Nephropathy, Nephrotic Syndrome in Children, and additional conditions. The research pipeline includes EARLY_Phase 1, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a The Children's Hospital of Zhejiang University School of Medicine clinical trial?
To participate in a The Children's Hospital of Zhejiang University School of Medicine trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all The Children's Hospital of Zhejiang University School of Medicine trials with current recruitment status updated daily.
Clinical Trials by The Children's Hospital of Zhejiang University School of Medicine
NCT06792799 EARLY_Phase 1
Recruiting
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
Autoimmune Diseases
NCT05734794 Phase 3
Recruiting
Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial
Nephrotic Syndrome in Children
NCT07113808
Recruiting
Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China
Abdominal Neoplasm
NCT06508346
Recruiting
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV
ANCA Associated Vasculitis
NCT06539624
Recruiting
Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
Fabry Disease
NCT07507201 EARLY_Phase 1
Recruiting
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
Autoimmune Diseases
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology